Emmaus Life Sciences, Inc. has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, where Endari is available on an early access basis only. Endari is approved in the U.S., the United Arab Emirates, Israel, and the State of Qatar to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Endari is available on an early access basis in Bahrain, Kuwait and the Kingdom of Saudi Arabia pending official notice of action on Emmaus's marketing authorization applications in those countries.